Please login to the form below

Not currently logged in
Email:
Password:

NICE rejects Keytruda for advanced bladder cancer in final guidance

Treatment had been authorised for use in this indication via the Cancer Drugs Fund in 2018

The UK’s National Institute for Health and Care Excellence (NICE) has issued a second final appraisal document rejecting MSD’s Keytruda for the treatment of advanced bladder cancer.

MSD – known as Merck & Co in the US and Canada – had initially been granted authorisation for Keytruda (pembrolizumab) in advanced or metastatic urothelial carcinoma patients who had previously received platinum-based chemotherapy via NICE’s Cancer Drugs Fund in 2018.

As part of the managed access agreement, further evidence could be collected for Keytruda in this indication, which was then reviewed by NICE as part of its final decision.

NICE decided not to issue a permanent recommendation for Keytruda in this patient population in March 2020, after results from the KEYNOTE-045 demonstrated a benefit for overall survival but not for progression-free survival in the second-line setting.

Following this rejection, MSD appealed the decision, although NICE has upheld its previous guidance not to recommend Keytruda as a second-line treatment for advanced bladder cancer patients.

In a statement issued today, NICE said that although evidence shows Keytruda meets its ‘life-extending treatment’ criteria, the cost-effectiveness estimate for the immunotherapy is uncertain.

‘This [uncertainty] is because it is not clear which adjustment for treatment switching or model of overall survival is most appropriate. It is also unclear how long the treatment benefit of pembrolizumab should continue,’ the cost-effectiveness watchdog added.

“Following the initial decision by the NICE committee not to recommend the use of pembrolizumab in this setting, we have done what we can to ensure continued access for patients,” said David Peacock, managing director, MSD.

“Following our successful appeal of the original decision, MSD was able to bring fresh data analyses and make a further offer on the patient access scheme to address the committee’s concerns.

“We feel strongly that the appeal was the right decision and that patient access to this medicine should have been maintained. MSD remains committed to research in bladder cancer, where unmet need endures, and we hope we can make meaningful positive impact through our science in the years ahead,” he added.

NICE said in its own statement that it now recommends Roche’s anti-PD-L1 drug Tecentriq (atezolizumab) for bladder cancer patients at this stage of the treatment pathway.

Article by
Lucy Parsons

18th March 2021

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite

Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....